MACROGENICS, INC. Increase (Decrease) in Accounts Payable and Other Operating Liabilities
MACROGENICS, INC. (MGNX) reported Increase (Decrease) in Accounts Payable and Other Operating Liabilities of $18.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities · last filed 2026-08-14
- MACROGENICS, INC. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2026-06-30 was $794.00K.
- MACROGENICS, INC. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2026-03-31 was -$776.00K, a 161.98% decline year-over-year.
- MACROGENICS, INC. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2025-09-30 was $1.31M, a 7.36% decline year-over-year.
- MACROGENICS, INC. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2025-06-30 was -$1.64M.
| Period end | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 3 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 6 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 9 month |
|---|---|---|---|
| 2026-06-30 | $794.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $18.00K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | -$776.00K 10-Q · filed 2026-05-13 | ||
| 2025-09-30 | $1.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$331.00K derived: sum of 2 quarters · filed 2026-08-14 | $921.00K 10-Q · filed 2025-11-12 |
| 2025-06-30 | -$1.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$388.00K 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $1.25M 10-Q · filed 2026-05-13 | ||
| 2024-09-30 | $1.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$4.01M derived: sum of 2 quarters · filed 2025-11-12 | $170.00K 10-Q · filed 2025-11-12 |
| 2024-06-30 | -$5.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$1.24M 10-Q · filed 2025-08-14 | |
| 2024-03-31 | $4.18M 10-Q · filed 2025-05-13 | ||
| 2023-09-30 | -$503.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$459.00K derived: sum of 2 quarters · filed 2024-11-05 | -$1.61M 10-Q · filed 2024-11-05 |
| 2023-06-30 | $44.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$1.10M 10-Q · filed 2024-08-06 | |
| 2023-03-31 | -$1.15M 10-Q · filed 2024-05-09 | ||
| 2022-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $1.02M derived: sum of 2 quarters · filed 2023-11-06 | -$10.90M 10-Q · filed 2023-11-06 |
| 2022-06-30 | -$976.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$12.90M 10-Q · filed 2023-08-09 | |
| 2022-03-31 | -$11.92M 10-Q · filed 2023-05-09 | ||
| 2021-09-30 | -$3.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$3.76M derived: sum of 2 quarters · filed 2022-11-03 | -$1.93M 10-Q · filed 2022-11-03 |
| 2021-06-30 | -$161.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $1.67M 10-Q · filed 2022-08-08 | |
| 2021-03-31 | $1.83M 10-Q · filed 2022-05-03 | ||
| 2020-09-30 | $1.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $2.42M derived: sum of 2 quarters · filed 2021-11-02 | $137.00K 10-Q · filed 2021-11-02 |
| 2020-06-30 | $810.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | -$1.48M 10-Q · filed 2021-07-29 | |
| 2020-03-31 | -$2.29M 10-Q · filed 2021-04-29 | ||
| 2019-09-30 | $1.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $1.62M derived: sum of 2 quarters · filed 2020-11-04 | -$913.00K 10-Q · filed 2020-11-04 |
| 2019-06-30 | -$67.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | -$2.60M 10-Q · filed 2020-07-31 | |
| 2019-03-31 | -$2.53M 10-Q · filed 2020-05-05 | ||
| 2018-09-30 | -$781.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$9.28M derived: sum of 2 quarters · filed 2019-11-06 | -$1.47M 10-Q · filed 2019-11-06 |
| 2018-06-30 | -$8.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | -$684.00K 10-Q · filed 2019-07-31 | |
| 2018-03-31 | $7.82M 10-Q · filed 2019-05-01 | ||
| 2017-09-30 | -$112.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $85.00K derived: sum of 2 quarters · filed 2018-11-07 | -$2.14M 10-Q · filed 2018-11-07 |
| 2017-06-30 | $197.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | -$2.03M 10-Q · filed 2018-08-07 | |
| 2017-03-31 | -$2.22M 10-Q · filed 2018-05-07 | ||
| 2016-09-30 | -$133.00K 10-Q · filed 2017-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |